dengu
import
arthropodborn
viral
diseas
human
increas
public
health
concern
tropic
subtrop
region
world
approxim
million
case
dengu
fever
df
case
dengu
hemorrhag
fever
dhf
occur
everi
year
billion
peopl
risk
dengu
infect
global
dengu
infect
may
lead
fever
headach
joint
pain
milder
case
may
also
lead
sever
lifethreaten
dhfdengu
shock
syndrom
dss
plasma
leakag
thrombocytopenia
hemorrhag
manifest
possibl
lead
shock
dengu
viru
denv
positivesens
singlestrand
rna
viru
approxim
kb
genom
genu
flaviviru
famili
flavivirida
four
genet
antigen
relat
viral
serotyp
flavivirus
encod
singl
polyprotein
process
host
viral
proteas
produc
three
structur
protein
includ
capsid
c
protein
precursor
membranemembran
prmm
envelop
e
protein
seven
nonstructur
protein
e
protein
kda
glycoprotein
import
attach
entri
viral
envelop
fusion
bind
cellular
receptor
induc
neutral
antibodi
denv
consist
icosahedr
ectodomain
contain
copi
e
protein
e
protein
monom
contain
three
structur
function
domain
e
protein
domain
edi
central
structur
e
protein
domain
ii
edii
organ
two
long
fingerlik
structur
contain
flavivirus
conserv
fusion
loop
e
protein
domain
iii
ediii
immunoglobulinlik
fold
may
mediat
interact
viru
receptor
host
cell
studi
biolog
characterist
epitop
specif
mous
monoclon
antibodi
mab
elucid
antigen
structur
flaviviru
e
protein
serotypespecif
mab
neutral
activ
found
locat
later
ridg
ediii
subcomplexspecif
mab
recogn
astrand
ediii
antibodymedi
neutral
found
alter
arrang
viral
surfac
glycoprotein
prevent
cell
viral
attach
bind
antibodi
viral
surfac
interfer
viru
intern
membran
fusion
primari
denv
infect
believ
provid
lifelong
immun
reinfect
serotyp
howev
humor
immun
respons
denv
infect
complex
may
exacerb
diseas
heterolog
viru
infect
antibodydepend
enhanc
ade
dengu
pathogenesi
result
increas
effici
viru
infect
presenc
nonneutr
subneutr
concentr
anti
antiprm
immunoglobulin
attach
antibodyviru
complex
receptorbear
cell
monocyt
macrophag
lead
increas
viru
replic
better
understand
neutral
epitop
may
facilit
gener
new
antibodybas
therapeut
denv
infect
studi
gener
sever
mab
found
serotypespecif
antiediii
mab
play
import
role
neutral
viru
infect
studi
neutral
epitop
found
strongest
mab
serotypespecif
antibodi
two
mab
recogn
astrand
ediii
residu
respect
human
mab
effici
neutral
infect
therapeut
mous
model
variant
version
prevent
enhanc
activ
cell
grown
minim
essenti
medium
mem
gibco
supplement
heatinactiv
fetal
bovin
serum
fb
gibco
uml
penicillin
streptomycin
amphotericin
b
antibioticantimycot
gibco
aed
albopictu
cell
grown
mitsuhashi
maramorosch
mm
insect
medium
sigmaaldrich
dulbecco
modifi
eagl
medium
dmem
gibco
contain
fb
uml
penicillin
streptomycin
amphotericin
b
antibioticantimycot
gibco
four
denv
hawaii
provid
dr
duan
j
gubler
center
diseas
control
prevent
fort
collin
usa
variou
strain
includ
new
guineac
ngc
ngcn
mouseadapt
neurovirul
malaysia
use
studi
virus
passag
cell
mab
gener
accord
previous
describ
procedur
femal
balbc
mice
immun
plaqueform
unit
pfu
purifi
viral
cultur
supernat
use
anti
protein
mab
coupl
protein
gsepharos
fast
flow
gel
four
inocul
concentr
antigen
splenocyt
immun
mous
spleen
harvest
fuse
mous
myeloma
cell
fuse
cell
cultur
dmem
supplement
fb
hat
medium
hybridoma
clone
factor
roch
tissu
cultur
plate
two
week
fusion
cultur
supernat
screen
elisa
select
clone
subclon
limit
dilut
hybridoma
clone
isotyp
use
commerci
isotyp
kit
southern
biotech
elisa
ascit
fluid
produc
pristineprim
balbc
mice
mab
affinitypurifi
standard
protein
gsepharos
fast
flow
ge
healthcar
bioscienc
accord
manufactur
direct
cell
confluenc
plate
infect
produc
viral
antigen
cell
harvest
day
infect
one
mab
ad
plate
incub
room
temperatur
rt
h
wash
pb
horseradish
peroxidas
hrp
conjug
antimous
igg
jackson
immunoresearch
laboratori
incub
rt
h
final
plate
incub
peroxidas
substrat
ophenylenediamin
dihydrochlorid
opd
sigmaaldrich
reaction
stop
hcl
optic
densiti
measur
use
micropl
reader
set
nm
cell
harvest
viral
infect
lysat
express
protein
collect
cell
extract
mix
sampl
buffer
biorad
laboratori
protein
sampl
separ
sdspage
transfer
nitrocellulos
membran
hybondc
super
nonspecif
antibodybind
site
block
skim
milk
pb
membran
incub
primari
antibodi
blot
treat
horseradish
peroxidaseconjug
goat
antimous
immunoglobulin
jackson
immunoresearch
laboratori
develop
enhanc
chemiluminesc
reagent
ecl
thermo
fisher
scientif
cell
confluenc
infect
multipl
infect
moi
day
infect
cell
fix
methanolaceton
min
cell
block
use
pb
supplement
bsa
h
rt
primari
antidenv
antibodi
control
antibodi
normal
mous
igg
jackson
immunoresearch
laboratori
dilut
block
solut
h
rt
secondari
antibodi
fitcconjug
goat
antimous
igg
jackson
immunoresearch
laboratori
dilut
supplement
dapi
invitrogen
dilut
h
rt
bind
activ
antibodi
transfect
cell
observ
photograph
fluoresc
microscop
express
construct
ediii
ediii
clone
vector
merck
ediii
compris
amino
acid
e
protein
tag
flag
hexahistidin
c
terminu
affin
purif
ediii
compris
amino
acid
e
protein
tag
flag
hexahistidin
plasmid
express
escherichia
coli
strain
recombin
protein
ediii
ediii
analyz
use
sdspage
western
blot
analysi
dna
fragment
correspond
ediii
ediii
also
clone
mammalian
express
vector
invitrogen
express
construct
c
prm
prme
e
obtain
dr
yl
lin
transient
express
protein
cell
transfect
polyjet
signagen
laboratori
accord
manufactur
recommend
test
specif
mab
plaqu
reduct
neutral
test
prnt
eight
serial
dilut
mab
mix
equal
volum
pfu
incub
h
final
concentr
mab
prnt
rang
antibodyviru
mixtur
ad
cell
confluenc
plate
absorpt
viru
h
cell
wash
ml
wv
carboxyl
methyl
cellulos
sigmaaldrich
mem
plu
vv
fb
layer
onto
infect
cell
incub
day
viral
plaqu
form
cell
monolay
fix
ml
formaldehyd
sigmaaldrich
rt
h
cell
stain
crystal
violet
percentag
plaqu
reduct
calcul
inhibit
plaqu
number
incub
mabplaqu
number
without
mab
ii
flow
cytometri
serial
dilut
mab
incub
ngc
malaysia
moi
h
ad
cell
h
absorpt
monolay
wash
incub
mem
gibco
plu
vv
fb
day
cell
infect
wash
fix
formaldehyd
min
permeabil
pb
supplement
fb
saponin
sigma
min
stain
cell
incub
concentr
min
two
wash
rphycoerythrin
pe
conjug
affinipur
f
fragment
goat
antimous
igg
hl
jackson
immunoresearch
laboratori
dilut
ad
min
follow
two
wash
analyz
flow
cytometri
infect
intens
cell
incub
mabwithout
mab
studi
carri
follow
strict
guidelin
care
use
manual
nation
laboratori
anim
center
protocol
approv
committe
ethic
anim
experi
academia
sinica
permit
number
mice
kill
contain
effort
made
minim
suffer
breeder
mice
icr
strain
purchas
laboratori
anim
center
nation
taiwan
univers
colleg
medicin
purifi
mab
dose
incub
pfu
min
twodayold
suckl
mous
brain
inocul
reaction
mixtur
intracrani
ic
inject
surviv
rate
sign
ill
includ
paralysi
observ
daili
day
follow
challeng
postexposur
therapeut
experi
mice
passiv
inject
mab
via
ic
rout
day
infect
ii
mice
bred
specificpathogenfre
anim
facil
institut
biomed
scienc
academia
sinica
mice
challeng
intraperiton
pfu
ngcn
pb
simultan
inject
intracrani
ic
pb
prophylaxi
experi
antibodi
per
mous
intraperiton
administ
day
infect
administ
day
infect
postexposur
therapeut
experi
antibodi
per
mous
intraperiton
administ
day
infect
phage
display
biopan
procedur
perform
accord
previou
report
briefli
elisa
plate
coat
mab
sampl
dilut
mab
ad
well
incub
h
wash
block
phagedisplay
peptid
librari
new
england
biolab
inc
dilut
pfu
phage
incub
min
rt
wash
bound
phage
elut
glycinehcl
ph
neutral
trishcl
ph
elut
phage
amplifi
subsequ
round
select
phage
titrat
onto
lb
medium
plate
contain
iptg
xgal
biopan
protocol
second
third
round
ident
first
round
except
addit
pfu
amplifi
phage
biopan
elisa
plate
coat
mab
wash
block
amplifi
phage
dilut
ad
coat
plate
incub
rt
h
wash
dilut
hrpconjug
antibodi
ge
healthcar
ad
rt
h
opd
develop
termin
hcl
optic
densiti
measur
nm
use
recombin
express
plasmid
gener
vlp
mutant
variou
vlp
mutant
gener
sitedirect
mutagenesi
deriv
templat
pcr
perform
use
pfu
ultra
dna
polymeras
merck
mutant
construct
confirm
sequenc
cell
confluenc
plate
transfect
plasmid
variou
vlp
two
day
transfect
cell
wash
pb
supplement
fb
fix
formaldehyd
min
permeabil
pb
supplement
fb
saponin
sigmaaldrich
min
stain
cell
incub
mab
min
mix
mab
concentr
respect
wash
twice
rphycoerythrin
pe
conjug
affinipur
f
fragment
goat
antimous
igg
hl
jackson
immunoresearch
laboratori
dilut
ad
min
analyz
flow
cytometri
rel
recognit
perform
accord
previous
describ
procedur
calcul
intens
mutant
vlpintens
wt
vlp
recogn
mab
intens
wt
vlpintens
mutant
vlp
recogn
mix
mab
total
rna
extract
hybridoma
cell
use
trizol
reagent
invitrogen
mrna
isol
nucleotrap
mrna
mini
kit
machereynagel
gmbh
co
kg
purifi
mrna
revers
transcrib
use
oligo
dt
primer
thermoscript
rtpcr
system
invitrogen
variabl
heavi
lightchain
domain
vh
vl
amplifi
cdna
product
pcr
varieti
primer
set
pcr
product
clone
use
ta
kit
promega
vh
vl
sequenc
determin
dna
sequenc
softwar
vector
nti
use
sequenc
analysi
sequenc
framework
region
fr
complementaritydetermin
region
cdr
analyz
compar
found
kabat
databas
immunogenet
databas
two
human
gene
genbank
access
ident
vh
vl
respect
human
vh
consist
modifi
access
gene
vh
respect
human
vl
consist
modifi
fr
access
gene
cdr
vl
synthes
geneart
amplifi
pcr
use
pfu
turbo
dna
polymeras
emd
bioscienc
result
vh
clone
modifi
express
vector
invitrogen
signal
peptid
human
constant
region
vl
clone
modifi
express
vector
psectag
invitrogen
gener
variant
human
variant
leucin
residu
posit
domain
substitut
alanin
residu
vh
vl
plasmid
cotransfect
cell
select
g
puromycin
week
transform
cell
limit
dilut
plate
two
week
stabl
clone
produc
human
antibodi
mccoy
medium
sigmaaldrich
identifi
elisa
human
antibodi
produc
cellin
ad
integra
bioscienc
accord
manufactur
direct
murin
human
mab
affin
analysi
ediii
perform
surfac
plasmon
reson
biacor
x
biacor
inc
purifi
ediii
immobil
sensor
chip
biacor
inc
inject
flow
rate
mab
dilut
nm
hbsep
buffer
biacor
inc
mab
inject
flow
rate
min
allow
dissoci
min
regener
surfac
achiev
inject
mm
glycin
nacl
ph
mab
inject
data
analyz
biaevalu
softwar
global
fit
bind
model
serial
dilut
mab
mix
moi
h
mixtur
incub
cell
plate
h
infect
cell
wash
incub
rpmi
gibco
plu
vv
fb
day
cell
wash
pb
supplement
fb
fix
formaldehyd
permeabil
pb
supplement
fb
saponin
sigma
min
stain
cell
incub
concentr
min
two
time
wash
rphycoerythrin
pe
conjug
affinipur
f
fragment
goat
antimous
igg
hl
jackson
immunoresearch
laboratori
west
grove
pa
dilut
ad
min
follow
two
time
wash
step
analyz
flow
cytometri
surviv
rate
express
use
kaplanmei
surviv
curv
log
rank
test
use
determin
signific
differ
bodi
weight
chang
experi
pair
ttest
use
determin
signific
differ
p
p
seventeen
mab
high
reactiv
e
protein
gener
immun
mice
strain
identifi
mab
belong
igg
isotyp
react
cell
mockinfect
cell
use
immunofluoresc
assay
ifa
figur
elisa
figur
panflaviviru
mab
could
recogn
fusion
loop
ediii
atcc
serotypespecif
mab
could
recogn
later
ridg
ediii
use
posit
control
figur
specif
mab
recogn
four
denv
confirm
elisa
western
blot
figur
tabl
base
western
blot
analysi
use
nonreduc
condit
mab
recogn
e
protein
kda
figur
three
mab
could
identifi
western
blot
order
identifi
target
protein
mab
prepar
cell
transfect
plasmid
express
c
prm
prme
e
figur
result
indic
three
mab
recogn
e
protein
figur
identif
character
mab
summar
tabl
character
antigen
structur
denv
e
protein
studi
relationship
epitop
neutral
potenc
construct
express
recombin
ediii
ediii
e
coli
mammalian
express
system
western
blot
analysi
ifa
show
mab
recogn
e
protein
mab
target
ediii
mab
recogn
ediii
figur
tabl
howev
mab
could
identifi
two
assay
evalu
abil
mab
inhibit
infect
cell
use
plaqu
reduct
neutral
test
prnt
ten
mab
neutral
activ
prnt
concentr
rang
tabl
found
serotypespecif
mab
ediii
figur
effici
neutral
infect
concentr
figur
addit
could
complet
inhibit
infect
lower
concentr
figur
mab
found
serotypespecif
mab
ediii
figur
neutral
titer
figur
find
indic
serotypespecif
mab
ediii
potent
neutral
denv
infect
serotypespecif
mab
ediii
ediii
show
strong
neutral
activ
mani
complex
reactiv
mab
show
moderatetopoor
neutral
activ
tabl
two
differ
mous
model
use
assess
whether
could
effici
protect
mice
challeng
protect
assay
neutral
mab
perform
icr
strain
suckl
mice
mice
inocul
intracerebr
mixtur
contain
pfu
neutral
mab
concentr
gener
nonneutr
antibodi
normal
mous
igg
nmigg
treat
group
show
paralysi
ruffl
slow
activ
around
day
follow
sever
sick
lead
anorexia
asthenia
death
within
day
figur
contrast
mab
concentr
protect
mice
lethal
challeng
figur
mab
surviv
rate
respect
surviv
rate
respect
figur
neutral
mab
show
signific
delay
onset
paralysi
death
rel
nmigg
evalu
therapeut
potenti
highli
protect
mab
administ
infect
suckl
mice
surviv
rate
respect
figur
comparison
show
surviv
rate
respect
mice
lack
transcript
factor
involv
interferon
ifn
signal
sensit
lethal
induc
infect
test
potenti
therapeut
effect
strongest
neutral
mab
challeng
mice
strict
condit
pfu
ngcn
day
observ
mice
show
ruffl
fur
mild
paralysi
lost
approxim
initi
bodi
weight
day
infect
p
die
within
day
infect
figur
prophylaxi
experi
antibodi
per
mous
intraperiton
administ
day
infect
day
infect
prophylact
treat
group
show
protect
figur
left
even
postexposur
therapeut
experi
treat
mice
surviv
rate
figur
left
mab
excel
neutral
activ
differ
strain
ngcn
two
mous
model
evalu
whether
strongest
mab
could
broadli
neutral
divers
strain
infect
cell
four
differ
southeast
asian
genotyp
strain
ngc
malaysia
remark
mab
exhibit
effect
neutral
variou
strain
figur
epitop
recogn
neutral
antibodi
identifi
three
domain
e
protein
find
epitop
neutral
antibodi
use
phage
display
identifi
neutral
epitop
three
round
phage
display
biopan
phage
titer
increas
compar
phage
display
biopan
result
first
round
figur
individu
phage
clone
third
round
biopan
randomli
select
elisa
perform
determin
whether
mab
could
specif
recogn
select
phage
clone
select
phage
clone
clone
signific
enhanc
bind
activ
respect
figur
select
phage
clone
specif
dose
depend
bound
respect
react
control
nmigg
figur
immunoposit
phage
clone
highli
reactiv
amplifi
phage
dna
isol
dna
sequenc
phage
clone
display
amino
acid
aa
residu
figur
left
phagedisplay
peptid
sequenc
select
consensu
motif
histidin
h
lysin
k
glutam
acid
e
tryptophan
w
tyrosin
histidin
h
figur
left
similarli
immunoposit
phage
clone
select
use
phage
librari
display
amino
acid
residu
contain
consensu
motif
hkewyh
figur
left
interestingli
phagedisplay
peptid
select
contain
lysin
k
glutam
acid
e
respect
figur
confirm
neutral
epitop
develop
variou
e
protein
epitopespecif
variant
vlp
screen
lossofbind
vlp
mutant
identif
critic
recognit
residu
use
strategi
found
lost
vlp
bind
activ
residu
astrand
ediii
chang
alanin
glutamin
figur
left
similarli
lost
vlp
bind
activ
chang
arginin
astrand
ediii
figur
right
critic
recognit
residu
locat
astrand
ediii
figur
found
mab
recogn
residu
figur
previous
report
notabl
even
adjac
residu
induc
antibodi
differ
level
neutral
activ
compar
amino
acid
sequenc
e
protein
repres
genotyp
tabl
found
residu
ediii
differ
genotyp
southeast
asian
west
african
american
figur
data
show
epitop
astrand
ediii
import
induc
neutral
antibodi
murin
mab
shown
limit
clinic
use
short
serum
halflif
inabl
trigger
human
effector
function
product
human
antimurin
antibodi
hama
respons
mab
human
graft
cdr
onto
vh
vl
fr
human
ig
molecul
potent
mab
show
potenti
therapeut
antibodi
develop
human
mab
sequenc
vh
vl
segment
neutral
mab
hybridoma
cell
line
cdr
graft
onto
human
backbon
creat
human
figur
express
cell
purifi
cultur
supernat
abl
figur
maintain
specif
murin
furthermor
establish
stabl
clone
select
mab
found
highli
bind
activ
figur
compar
mab
found
highest
product
rate
cell
mab
dosedepend
ediii
figur
affin
analyz
surfac
plasmon
reson
bound
ediii
similar
affin
nm
nm
respect
figur
result
reveal
maintain
bind
affin
e
protein
establish
suckl
mice
model
determin
protect
activ
evalu
therapeut
effect
mab
administ
mab
day
one
pfu
infect
day
observ
group
treat
mab
found
surviv
rate
respect
figur
howev
none
mice
control
antibodi
normal
human
igg
nhigg
treat
group
surviv
figur
result
demonstr
excel
neutral
activ
develop
antibodybas
therapi
ade
phenomenon
major
caus
concern
dengu
pathogenesi
might
enhanc
denv
infect
modif
fc
structur
antibodi
prevent
receptor
bind
lead
elimin
ade
gener
variant
human
variant
prevent
receptor
bind
maintain
denv
neutral
capabl
without
enhanc
infect
figur
variant
retain
neutral
activ
unmodifi
mab
high
concentr
complet
devoid
enhanc
activ
low
concentr
figur
variant
elimin
ade
phenomenon
hold
great
potenti
develop
therapeut
antibodi
prevent
treatment
infect
mab
denv
serv
power
research
tool
antivir
develop
patholog
investig
newli
gener
character
mab
high
reactiv
e
protein
sever
mab
potent
neutral
activ
neutral
epitop
identifi
use
combin
strategi
includ
phage
display
comput
structur
analysi
highthroughput
epitop
map
vlp
result
astrand
ediii
found
import
neutral
later
ridg
ediii
mab
strongest
neutral
activ
variou
strain
human
modifi
abrog
ade
phenomenon
mab
demonstr
increas
surviv
rate
two
mous
model
even
infect
base
previou
epitop
map
result
sever
epitop
shown
elicit
strong
neutral
antibodi
individu
flavivirus
situat
ediii
investig
neutral
epitop
e
protein
may
provid
framework
detail
understand
specif
mechan
viral
infect
well
identif
specif
denv
domain
attach
cellular
receptor
phage
display
use
identif
bcell
epitop
includ
linear
conform
epitop
howev
epitop
need
elucid
use
method
combin
differ
strategi
provid
fast
reliabl
evid
identifi
epitop
figur
date
mab
possess
better
neutral
activ
shown
bind
residu
later
ridg
ediii
higher
neutral
activ
neutral
epitop
map
residu
astrand
ediii
figur
neutral
epitop
anoth
mab
map
residu
astrand
ediii
figur
serotypespecif
neutral
epitop
locat
astrand
ediii
induc
stronger
neutral
activ
locat
later
ridg
ediii
align
differ
genotyp
found
frequent
observ
figur
may
import
thu
bind
lead
dramat
neutral
determin
whether
neutral
divers
genotyp
critic
step
evalu
potenti
therapeut
develop
futur
previou
studi
shown
strongli
neutral
mab
subcomplexspecif
crossreact
recogn
residu
astrand
mab
serotypespecif
neutral
mab
recogn
residu
residu
although
consid
subcomplexspecif
epitop
serotypespecif
mab
may
region
affect
bind
found
mutat
residu
bind
activ
reduc
data
shown
residu
may
minor
epitop
moreov
temperatur
depend
mab
due
need
dynam
motion
virion
surfac
neutral
viru
differ
temperatur
independ
incub
denv
still
exhibit
signific
neutral
activ
figur
expect
incub
denv
show
better
efficaci
data
shown
residu
surfac
may
access
bind
addit
high
bind
affin
nm
base
find
residu
induc
serotypespecif
mab
crucial
neutral
viru
infect
antibodi
ediii
tend
crossreact
less
potent
neutral
dengu
infect
howev
fewer
antibodi
concentr
capabl
recogn
ediii
recogn
ediii
dengu
patient
wahala
et
al
studi
human
immun
sera
denv
infect
found
ediii
bind
antibodi
play
minor
role
denv
neutral
similar
west
nile
virusinfect
human
mab
bind
ediii
express
potent
neutral
activ
exist
serum
patient
infect
denv
wnv
combin
inform
mice
human
mab
studi
denv
infect
critic
understand
complex
mechan
behind
humor
immun
follow
natur
denv
infect
accord
one
previou
studi
immunoglobulin
popul
recogn
residu
dengu
fever
patient
much
larger
igm
igg
strong
neutral
igg
made
small
proport
antibodi
dengu
patient
de
alwi
et
al
conduct
indepth
analysi
human
mab
deriv
memori
bcell
patient
infect
primari
denv
infect
epitop
map
human
mab
strong
neutral
mab
map
astrand
togeth
find
suggest
highli
protect
epitop
mous
play
role
human
well
also
identifi
sever
ediii
specif
mab
high
neutral
activ
serotypespecif
mab
potent
neutral
activ
found
recogn
ediii
figur
tabl
studi
identifi
highli
neutral
protect
antibodi
jev
denv
locat
edi
current
process
identifi
neutral
epitop
mab
broadli
crossreact
flavivirus
edii
near
fusion
loop
immunodomin
antigen
bind
antibodi
denv
chang
rearrang
e
protein
may
neutral
enhanc
viral
infect
high
neutral
activ
mab
use
help
identifi
neutral
immunopathogen
epitop
e
protein
studi
explor
mab
mediat
neutral
mechan
mab
depend
enhanc
current
underway
mous
model
dengu
infect
develop
date
repres
entireti
pathogenesi
human
dengu
infect
develop
mous
model
studi
pathogenesi
import
challeng
use
two
model
suckl
mice
protect
assay
mous
model
differ
strain
intracerebr
intraperiton
inocul
evalu
neutral
activ
mab
figur
find
suggest
mab
might
effect
block
viru
entri
howev
diseas
manifest
suckl
mice
relev
dengu
diseas
human
sinc
denv
infect
human
rare
involv
nervou
system
mice
genet
mutat
immunocompet
henc
repres
wild
type
immun
respons
denv
howev
surviv
rate
might
reflect
therapeut
potenti
mab
result
mous
model
show
therapeut
potenti
newli
gener
mab
worth
investig
absenc
effect
dengu
vaccin
neutral
antibodi
use
passiv
immunotherapeut
strategi
treat
dengu
previou
studi
human
antibodi
denv
deriv
two
chimpanze
fab
fragment
human
crossneutr
human
specif
newli
gener
deriv
murin
mab
howev
develop
antibodybas
therapi
ade
phenomenon
major
concern
modif
fc
structur
antibodi
prevent
receptor
bind
inhibit
ade
figur
studi
show
serotypespecif
mab
target
astrand
ediii
could
serv
dramat
neutral
determin
test
differ
mous
model
success
gener
mab
variant
high
therapeut
potenti
divers
strain
without
induc
ade
antibodybas
therapi
may
help
control
sever
dengu
futur
